Sean Geraghty > Dechert LLP > London, England > Lawyer Profile

Dechert LLP

Work Department



Sean Geraghty’s experience includes mergers and acquisitions (both public and private, for corporate clients and private equity clients), IPOs (on the Official List, AIM and overseas), secondary offerings, joint ventures and general corporate matters. Mr Geraghty has acted for major European and international corporate clients and financial institutions on substantial transactions.


Partner 2006. Publications of note: ‘Annotated Guide to the Companies Act’ (chapter in the Oxford University Press, 2006); ‘Hedge Funds and the Law’ (Sweet & Maxwell); contributing editor ‘Company Directors: Law and Liability’ (Sweet & Maxwell).


QCA’s Corporate Finance Advisers Expert Group.


Exeter University (1991 BA Economics).

Lawyer Rankings

London > Corporate and commercial > M&A: upper mid-market and premium deals, £500m+

(Leading individuals)

Sean GeraghtyDechert LLP

The London office of Dechert LLP enjoys a sterling reputation in the financial services M&A space, advising on domestic and cross-border transactions for various  banks. Over the past year the team has been regularly engaged on fintech transactions, as well as handling deals for clients in the consumer, retail, life sciences, and TMT space. Practice head Douglas Getter regularly represents private and publicly-listed companies on international M&A deals, while Sean Geraghty is known for his deep expertise in the TMT sector.

London > Corporate and commercial > Equity capital markets – small-mid cap

Dechert LLP‘s team is highly active in transactions spanning a number of key markets, including London, New York and Paris; it is also notably strong in deals connected with North Africa and the Middle East, particularly Lebanon and Egypt. Patrick Lyons and Sean Geraghty co-head the group in London, which delivers US and UK securities law advice. The life sciences sector is a key area of strength for the firm, as was evidenced in 2020, when Lyons worked with members of the Paris office to assist gene therapy platform company Lysogene with a €7.7m capital increase. Jennifer Rees made partner.